We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Amphastar Pharmaceuticals announced Tuesday that the FDA issued a complete response letter regarding the company's filing seeking approval of intranasal naloxone for the emergency treatment of known or suspected opioid overdose.